EP Patent

EP4491229A2 — Coding rna administered into the suprachoroidal space in the treatment of ophtalmic diseases

Assigned to Curevac SE · Expires 2025-01-15 · 1y expired

What this patent protects

The invention relates inter alia to compositions comprising coding RNA for use in treatment of an ophthalmic disease, disorder or condition, wherein said composition is administered into the suprachoroidal space of a subject in need of treatment. Additionally, methods of treati…

USPTO Abstract

The invention relates inter alia to compositions comprising coding RNA for use in treatment of an ophthalmic disease, disorder or condition, wherein said composition is administered into the suprachoroidal space of a subject in need of treatment. Additionally, methods of treating or preventing ophthalmic diseases, disorders or conditions are provided.

Drugs covered by this patent

Patent Metadata

Patent number
EP4491229A2
Jurisdiction
EP
Classification
—
Expires
2025-01-15
Drug substance claim
No
Drug product claim
No
Assignee
Curevac SE
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.